Home Biosimilar Antibodies Cytoskeletal Signaling Integrin Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1))
For research use only. Not for use in humans.

Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1))

Synonyms: VLA-5， Integrin alpha5beta1

Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD.

Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1))

Quality Control

Batch: A310602 Purity: 99% Protein concentration: 9.96mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation Integrin ILK Others
Cilengitide trifluoroacetate 71
A-205804 7
GLPG0187 1
GSK-3008348 HCl 0
Bexotegrast (PLN-74809) 1
Cilengitide (EMD 121974) 37
OSU-T315 1
TR-14035 0
Cyclo(RGDyK) TFA 15
SB273005 27
RGD peptide (Arg-Gly-Asp) 27
ILK-IN-3 1
RGD peptide (GRGDNP) 5 caspase-3
ATN-161 22
Cyclo(-RGDfK) TFA 14
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD.
References

Product Details

CAS No. 558480-40-3
Isotype Human IgG4SP
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00782093 COMPLETED Drug: volociximab Age-related Macular Degeneration Ophthotech Corporation 2008-10 PHASE1
NCT00654758 COMPLETED Drug: M200 (Volociximab), Carboplatin, Paclitaxel Non-small Cell Lung Cancer AbbVie 2007-12 PHASE1
NCT00666692 COMPLETED Drug: M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizum Non-small Cell Lung Cancer Abbott 2008-04 PHASE1
NCT00635193 COMPLETED Drug: M200 (Volociximab)|Drug: Liposomal Doxorubicin|Drug: M Ovarian Cancer, Primary Peritoneal Cancer AbbVie (prior sponsor, Abbott) 2007-07 PHASE1; PHASE2
NCT00401570 COMPLETED Drug: Volociximab|Drug: Gemcitabine Pancreatic Cancer AbbVie (prior sponsor, Abbott) 2005-03 PHASE2
NCT00516841 TERMINATED Drug: Volociximab Ovarian Cancer; Peritoneal Neoplasms Facet Biotech 2007-08 PHASE2

(data from https://clinicaltrials.gov, updated on 2024-02-21)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.